Patient number | Gender | Age/yrs | Weight at start of TCZ | Disease | Follow up (FU)/mo | Indication for TCZ | Pred. before TCZ/mg* | Pred. at last FU | Specifics |
---|---|---|---|---|---|---|---|---|---|
1 | m | 62 | 77 | GCA+PMR | 25 | toxicity of pretreatment | 10 | 1,5 | - |
2 | f | 77 | 75 | GCA+PMR | 19 | toxicity of pretreatment | 5 | 1 | - |
3 | f | 61 | 62 | GCA | 4 | active vasculitis | 7,5 | 10 | Colitis, switch to abatacept |
4 | f | 62 | 64 | LVV+RA | 20 | active vasculitis | 5 | 7,5 | Died in remission after aortic arc replacement |
5 | m | 80 | 92 | GCA+PMR | 4 | active vasculitis | 100 | 100 | Died of E.coli sepsis with sigmoiditis |
6 | f | 66 | 69 | LVV+RA | 45 | active vasculitis | 5 | 2,5 | - |
7 | f | 52 | 60 | GCA+PMR | 60 | active vasculitis | 25 | 0 | - |
8 | m | 78 | 81 | GCA+PMR | 17 | active vasculitis | 17,5 | 0 | - |
Switch from TCZ-SC to TCZ-IV due to relapse: | Prednisolone reduction (dose before pulse / dose at last follow-up under TCZ without relapse) |
||||||||
9 | f | 71 | 61 | GCA | 17 | active vasculitis | 5 | 20 | 5 mg / 5mg after 9 mo, relapse after perioperative stop of TCZ |
10 | f | 47 | 100 | GCA | 24 | active vasculitis | 7,5 | 3 | 5 mg / 3 mg after 24 mo |
11 | f | 21 | 57,5 | TAK | 20 | active vasculitis | 17,5 | 4 | 15 mg / 4 mg after 20 mo |